Tackling violence against women and girls is a moral mission for all of society, and education is an integral part. We are focussing on prevention; instilling the values and skills to disrupt dangerous attitudes and stop harmful behaviours from escalating.

We are supporting schools to challenge misogyny, launching major campaigns to raise awareness and change behaviour, and we are investing £16m to test the best ways to deliver the new RSHE curriculum, provide healthy relationships training and to help tackle harmful behaviours. This money will support teachers and schools in tackling this vital issue.

I look forward to an invitation from my hon. Friend and I pay tribute to his work as co-chair of the all-party parliamentary group. What he says about the voice of the community going forward is absolutely right. That is why I have created, and announced to the House, a mechanism by which concerns that are expressed are appropriately elevated to where decisions need to be made. I was determined not to have some sort of glorified post box that people sent correspondence into. If concerns are raised, they must be dealt with at the appropriate level, whether that is the Infected Blood Compensation Authority board, or escalated to the Cabinet Office.

It is crucial we protect the safety of haemophilia care, and the Government is committed to implementing recommendation 9 of the 2024 Infected Blood Inquiry report.

The Government is committed to improving the lives of those living with rare diseases, such as haemophilia. The UK Rare Diseases Framework sets out four priorities collaboratively developed with the rare disease community: these include getting a final diagnosis faster; increasing awareness of rare diseases among healthcare professionals; better coordination of care; and improving access to specialist care, treatments, and drugs. We published the fifth annual England action plan in February 2026, where we report on the steps we have taken to advance these priorities.

In relation to recommendation 9, a to c, of the Infected Blood Inquiry, peer review of United Kingdom comprehensive care centres has been an essential part of haemophilia services for many years. The triennial audit was replaced in 2019 with a more formal peer review process on a five-year cycle.

The final peer review report is expected to be published imminently and once published, it will be shared with the NHS England Specialised Commissioning Quality Oversight Group for consideration and action. This will be supported by a letter to integrated care boards and trust boards, emphasising the valuable role of peer review and asking for confirmation of their commitment to review and implement the peer review findings.

The Haemophilia Service Specification has been updated by the Blood Disorders Clinical Reference Group and is making its way through final approvals, having undergone public consultation. The new specification includes a contractual requirement for providers to participate in and act upon peer review findings.

Regarding 9d, the Clinical Community and the NHS England Clinical Reference Group for Blood Disorders supports the need to develop and strengthen multi-disciplinary networks. NHS England has drafted a proposed National Clinical Network Specification specifically for these networks, which is dependent on additional funding, and which would embed key new requirements for providers to participate in a networked model of care.

In response to 9e, all diseases or conditions where a non-plasma treatment exists to replace a plasma/blood-derived treatment are now addressed by commissioning policies or funding agreements. There are some specific regimens which are subject to ongoing clinical policy development but in each case there are alternative regimens or treatment approaches which negate the use of plasma-derived medicines.

Of particular interest to the clinical and patient community is the development of a clinical commissioning policy for recombinant Von Willebrand factor, which is currently licensed for prophylaxis in adults, as regular treatment for those with the severest bleeding, but which is not currently commissioned for this indication. Funding will be required to implement this clinical policy for all ages, and this has not yet been identified.

Finally, for 9f, NHS England currently provides ‘central’ funding of approximately 40% of the total annual cost for running the National Haemophilia Database. A task and finish group relating to the database has been established, reporting into the overarching recommendation 9 expert group.

As of February 2026, stakeholders involved in the recommendation 9f working group are in agreement that the registry has been and remains immensely valuable in supporting the provision of clinical care. NHS England continues to work with the United Kingdom Haemophilia Centres Doctors' Organisation to understand the requirement for increased funding.

Further progress on implementing recommendation 9 is subject to additional funding, and this has not yet been identified. NHS England and the Department will continue to work together to provide progress updates on the Government Reporting Integration Platform.

It is crucial we protect the safety of haemophilia care, and the Government is committed to implementing recommendation 9 of the 2024 Infected Blood Inquiry report.

The Government is committed to improving the lives of those living with rare diseases, such as haemophilia. The UK Rare Diseases Framework sets out four priorities collaboratively developed with the rare disease community: these include getting a final diagnosis faster; increasing awareness of rare diseases among healthcare professionals; better coordination of care; and improving access to specialist care, treatments, and drugs. We published the fifth annual England action plan in February 2026, where we report on the steps we have taken to advance these priorities.

In relation to recommendation 9, a to c, of the Infected Blood Inquiry, peer review of United Kingdom comprehensive care centres has been an essential part of haemophilia services for many years. The triennial audit was replaced in 2019 with a more formal peer review process on a five-year cycle.

The final peer review report is expected to be published imminently and once published, it will be shared with the NHS England Specialised Commissioning Quality Oversight Group for consideration and action. This will be supported by a letter to integrated care boards and trust boards, emphasising the valuable role of peer review and asking for confirmation of their commitment to review and implement the peer review findings.

The Haemophilia Service Specification has been updated by the Blood Disorders Clinical Reference Group and is making its way through final approvals, having undergone public consultation. The new specification includes a contractual requirement for providers to participate in and act upon peer review findings.

Regarding 9d, the Clinical Community and the NHS England Clinical Reference Group for Blood Disorders supports the need to develop and strengthen multi-disciplinary networks. NHS England has drafted a proposed National Clinical Network Specification specifically for these networks, which is dependent on additional funding, and which would embed key new requirements for providers to participate in a networked model of care.

In response to 9e, all diseases or conditions where a non-plasma treatment exists to replace a plasma/blood-derived treatment are now addressed by commissioning policies or funding agreements. There are some specific regimens which are subject to ongoing clinical policy development but in each case there are alternative regimens or treatment approaches which negate the use of plasma-derived medicines.

Of particular interest to the clinical and patient community is the development of a clinical commissioning policy for recombinant Von Willebrand factor, which is currently licensed for prophylaxis in adults, as regular treatment for those with the severest bleeding, but which is not currently commissioned for this indication. Funding will be required to implement this clinical policy for all ages, and this has not yet been identified.

Finally, for 9f, NHS England currently provides ‘central’ funding of approximately 40% of the total annual cost for running the National Haemophilia Database. A task and finish group relating to the database has been established, reporting into the overarching recommendation 9 expert group.

As of February 2026, stakeholders involved in the recommendation 9f working group are in agreement that the registry has been and remains immensely valuable in supporting the provision of clinical care. NHS England continues to work with the United Kingdom Haemophilia Centres Doctors' Organisation to understand the requirement for increased funding.

Further progress on implementing recommendation 9 is subject to additional funding, and this has not yet been identified. NHS England and the Department will continue to work together to provide progress updates on the Government Reporting Integration Platform.

It is crucial we protect the safety of haemophilia care, and the Government is committed to implementing recommendation 9 of the 2024 Infected Blood Inquiry report.

The Government is committed to improving the lives of those living with rare diseases, such as haemophilia. The UK Rare Diseases Framework sets out four priorities collaboratively developed with the rare disease community: these include getting a final diagnosis faster; increasing awareness of rare diseases among healthcare professionals; better coordination of care; and improving access to specialist care, treatments, and drugs. We published the fifth annual England action plan in February 2026, where we report on the steps we have taken to advance these priorities.

In relation to recommendation 9, a to c, of the Infected Blood Inquiry, peer review of United Kingdom comprehensive care centres has been an essential part of haemophilia services for many years. The triennial audit was replaced in 2019 with a more formal peer review process on a five-year cycle.

The final peer review report is expected to be published imminently and once published, it will be shared with the NHS England Specialised Commissioning Quality Oversight Group for consideration and action. This will be supported by a letter to integrated care boards and trust boards, emphasising the valuable role of peer review and asking for confirmation of their commitment to review and implement the peer review findings.

The Haemophilia Service Specification has been updated by the Blood Disorders Clinical Reference Group and is making its way through final approvals, having undergone public consultation. The new specification includes a contractual requirement for providers to participate in and act upon peer review findings.

Regarding 9d, the Clinical Community and the NHS England Clinical Reference Group for Blood Disorders supports the need to develop and strengthen multi-disciplinary networks. NHS England has drafted a proposed National Clinical Network Specification specifically for these networks, which is dependent on additional funding, and which would embed key new requirements for providers to participate in a networked model of care.

In response to 9e, all diseases or conditions where a non-plasma treatment exists to replace a plasma/blood-derived treatment are now addressed by commissioning policies or funding agreements. There are some specific regimens which are subject to ongoing clinical policy development but in each case there are alternative regimens or treatment approaches which negate the use of plasma-derived medicines.

Of particular interest to the clinical and patient community is the development of a clinical commissioning policy for recombinant Von Willebrand factor, which is currently licensed for prophylaxis in adults, as regular treatment for those with the severest bleeding, but which is not currently commissioned for this indication. Funding will be required to implement this clinical policy for all ages, and this has not yet been identified.

Finally, for 9f, NHS England currently provides ‘central’ funding of approximately 40% of the total annual cost for running the National Haemophilia Database. A task and finish group relating to the database has been established, reporting into the overarching recommendation 9 expert group.

As of February 2026, stakeholders involved in the recommendation 9f working group are in agreement that the registry has been and remains immensely valuable in supporting the provision of clinical care. NHS England continues to work with the United Kingdom Haemophilia Centres Doctors' Organisation to understand the requirement for increased funding.

Further progress on implementing recommendation 9 is subject to additional funding, and this has not yet been identified. NHS England and the Department will continue to work together to provide progress updates on the Government Reporting Integration Platform.

It is crucial we protect the safety of haemophilia care, and the Government is committed to implementing recommendation 9 of the 2024 Infected Blood Inquiry report.

The Government is committed to improving the lives of those living with rare diseases, such as haemophilia. The UK Rare Diseases Framework sets out four priorities collaboratively developed with the rare disease community: these include getting a final diagnosis faster; increasing awareness of rare diseases among healthcare professionals; better coordination of care; and improving access to specialist care, treatments, and drugs. We published the fifth annual England action plan in February 2026, where we report on the steps we have taken to advance these priorities.

In relation to recommendation 9, a to c, of the Infected Blood Inquiry, peer review of United Kingdom comprehensive care centres has been an essential part of haemophilia services for many years. The triennial audit was replaced in 2019 with a more formal peer review process on a five-year cycle.

The final peer review report is expected to be published imminently and once published, it will be shared with the NHS England Specialised Commissioning Quality Oversight Group for consideration and action. This will be supported by a letter to integrated care boards and trust boards, emphasising the valuable role of peer review and asking for confirmation of their commitment to review and implement the peer review findings.

The Haemophilia Service Specification has been updated by the Blood Disorders Clinical Reference Group and is making its way through final approvals, having undergone public consultation. The new specification includes a contractual requirement for providers to participate in and act upon peer review findings.

Regarding 9d, the Clinical Community and the NHS England Clinical Reference Group for Blood Disorders supports the need to develop and strengthen multi-disciplinary networks. NHS England has drafted a proposed National Clinical Network Specification specifically for these networks, which is dependent on additional funding, and which would embed key new requirements for providers to participate in a networked model of care.

In response to 9e, all diseases or conditions where a non-plasma treatment exists to replace a plasma/blood-derived treatment are now addressed by commissioning policies or funding agreements. There are some specific regimens which are subject to ongoing clinical policy development but in each case there are alternative regimens or treatment approaches which negate the use of plasma-derived medicines.

Of particular interest to the clinical and patient community is the development of a clinical commissioning policy for recombinant Von Willebrand factor, which is currently licensed for prophylaxis in adults, as regular treatment for those with the severest bleeding, but which is not currently commissioned for this indication. Funding will be required to implement this clinical policy for all ages, and this has not yet been identified.

Finally, for 9f, NHS England currently provides ‘central’ funding of approximately 40% of the total annual cost for running the National Haemophilia Database. A task and finish group relating to the database has been established, reporting into the overarching recommendation 9 expert group.

As of February 2026, stakeholders involved in the recommendation 9f working group are in agreement that the registry has been and remains immensely valuable in supporting the provision of clinical care. NHS England continues to work with the United Kingdom Haemophilia Centres Doctors' Organisation to understand the requirement for increased funding.

Further progress on implementing recommendation 9 is subject to additional funding, and this has not yet been identified. NHS England and the Department will continue to work together to provide progress updates on the Government Reporting Integration Platform.

It is crucial we protect the safety of haemophilia care, and the Government is committed to implementing recommendation 9 of the 2024 Infected Blood Inquiry report.

The Government is committed to improving the lives of those living with rare diseases, such as haemophilia. The UK Rare Diseases Framework sets out four priorities collaboratively developed with the rare disease community: these include getting a final diagnosis faster; increasing awareness of rare diseases among healthcare professionals; better coordination of care; and improving access to specialist care, treatments, and drugs. We published the fifth annual England action plan in February 2026, where we report on the steps we have taken to advance these priorities.

In relation to recommendation 9, a to c, of the Infected Blood Inquiry, peer review of United Kingdom comprehensive care centres has been an essential part of haemophilia services for many years. The triennial audit was replaced in 2019 with a more formal peer review process on a five-year cycle.

The final peer review report is expected to be published imminently and once published, it will be shared with the NHS England Specialised Commissioning Quality Oversight Group for consideration and action. This will be supported by a letter to integrated care boards and trust boards, emphasising the valuable role of peer review and asking for confirmation of their commitment to review and implement the peer review findings.

The Haemophilia Service Specification has been updated by the Blood Disorders Clinical Reference Group and is making its way through final approvals, having undergone public consultation. The new specification includes a contractual requirement for providers to participate in and act upon peer review findings.

Regarding 9d, the Clinical Community and the NHS England Clinical Reference Group for Blood Disorders supports the need to develop and strengthen multi-disciplinary networks. NHS England has drafted a proposed National Clinical Network Specification specifically for these networks, which is dependent on additional funding, and which would embed key new requirements for providers to participate in a networked model of care.

In response to 9e, all diseases or conditions where a non-plasma treatment exists to replace a plasma/blood-derived treatment are now addressed by commissioning policies or funding agreements. There are some specific regimens which are subject to ongoing clinical policy development but in each case there are alternative regimens or treatment approaches which negate the use of plasma-derived medicines.

Of particular interest to the clinical and patient community is the development of a clinical commissioning policy for recombinant Von Willebrand factor, which is currently licensed for prophylaxis in adults, as regular treatment for those with the severest bleeding, but which is not currently commissioned for this indication. Funding will be required to implement this clinical policy for all ages, and this has not yet been identified.

Finally, for 9f, NHS England currently provides ‘central’ funding of approximately 40% of the total annual cost for running the National Haemophilia Database. A task and finish group relating to the database has been established, reporting into the overarching recommendation 9 expert group.

As of February 2026, stakeholders involved in the recommendation 9f working group are in agreement that the registry has been and remains immensely valuable in supporting the provision of clinical care. NHS England continues to work with the United Kingdom Haemophilia Centres Doctors' Organisation to understand the requirement for increased funding.

Further progress on implementing recommendation 9 is subject to additional funding, and this has not yet been identified. NHS England and the Department will continue to work together to provide progress updates on the Government Reporting Integration Platform.

The milestones that were set out for paying infected people were met by the end of 2025. The first payment to an affected person was also on time, and was made before the end of last year. My hon. Friend is absolutely right that we are now moving into a new phase of paying affected people, which will clearly be a larger number. I will, of course, happily write to him with the precise figures on that.

We need to address the UK’s borrowing and debt, so we spend less on debt interest and more on the priorities of working people.

The government has a credible consolidation plan that ensures borrowing is falling in every year of the forecast. Borrowing this year is set to be the lowest for 6 years.

The government is reducing borrowing while protecting investment, and is maintaining an increase of over £120 billion departmental capital spending over the Parliament.

From 2025 to 2030, the UK is reducing government borrowing more than any other G7 country.

I am grateful to my hon. Friend for his question and the inequalities to which he draws our attention. We will look at that report carefully. I am awaiting the recommendation of the UK National Screening Committee. We will look carefully at that, and I will report to the House on our decision.

I have had several productive conversations with the chief coroner, looking at how we can make the inquest process as quick as possible to ensure that the bereaved are supported and not left traumatised waiting for their inquest. The Bill we are laying before Parliament today, the Hillsborough law, has many parts looking at how to improve the inquest process and it gives more powers to coroners. We are looking at what more we can do on the reform of inquests. I look forward to working with my hon. Friend and others on how to improve the coronial process.

I may be in the hands of Mr Speaker so I will certainly not tread on to which days I will be permitted to do so, but definitely before the summer recess.

I am deeply sympathetic to the inquiry’s words on the involvement of the infected blood community. The Government are committed to providing fair compensation to victims of this scandal. The inquiry recognised this and said:

“There can be no doubt that the Government has done right in ways which powerfully signal its intent.”

However, I also recognise what Sir Brian said when he stated that

“there is still more to be done to ensure that the detail and operation of the scheme matches up to its intent.”

I will now urgently look at those recommendations with a view to action.

The Department has asked NHS England to continue to progress work on the Infusions and Special Medicines Programme, which is tasked with the implementation of Lord Carter’ 2020 report, Transforming Pharmacy Aseptic Services in England. The work included publication of guidance for the quality assurance of aseptic production in National Health Service hospitals and improved audits in unlicensed aseptic medicines preparation units, using digital tools to improve the transparency of the work. These hospital aseptic medicines preparation units make unlicensed ‘special’ medicines, which include ready to administer chemotherapy injections and intravenous nutrition products. The majority of these units are regulated by the Care Quality Commission.

A minority of aseptic medicines preparation services in hospitals are licensed units with a Medicines and Healthcare products Regulatory Agency (MHRA) Specials Authorisation. These units are regulated by the MHRA.

The Department has asked NHS England to continue to progress work on the Infusions and Special Medicines Programme, which is tasked with the implementation of Lord Carter’ 2020 report, Transforming Pharmacy Aseptic Services in England. The work included publication of guidance for the quality assurance of aseptic production in National Health Service hospitals and improved audits in unlicensed aseptic medicines preparation units, using digital tools to improve the transparency of the work. These hospital aseptic medicines preparation units make unlicensed ‘special’ medicines, which include ready to administer chemotherapy injections and intravenous nutrition products. The majority of these units are regulated by the Care Quality Commission.

A minority of aseptic medicines preparation services in hospitals are licensed units with a Medicines and Healthcare products Regulatory Agency (MHRA) Specials Authorisation. These units are regulated by the MHRA.

I am grateful to my hon. Friend for the work he does with the all-party parliamentary group. He will know that the Infected Blood Compensation Authority has published a prioritisation list in recent months. I can also update the House that IBCA is contacting an average of 100 people every week to start their claim, and it expects in this calendar year to have brought in to claim all those who are infected and registered with a support scheme.

Today we are investing £15.6 billion in the transport infrastructure of the north and of the midlands. We are decisively turning the page on a failed economic model of low investment, and we are backing the talent and prospects of the whole country. Over the coming weeks we will set out plans for further investment and renewal.

Our strategic defence review shows that this Government will never gamble with our national security. Through the biggest sustained funding increase since the cold war, we will transform our defence, strengthen our nation and invest in jobs and industry across the United Kingdom.

This morning I had meetings with ministerial colleagues and others. In addition to my duties in this House, I shall have further such meetings later today.

One of the greatest achievements of the last Labour Government was the 2012 Olympics in London, and we all remember it—[Interruption.] Given that response, can I pay tribute to the extraordinary contribution of Tessa Jowell to those games? I agree that there have been huge economic benefits from hosting major sporting events as well as an important legacy.